Volume Alert - COV 96.94 Covidien Plc. $COV Hit a high today of 97.19 Closing the day 10:30 at 96.94 -0.56 -0.57% With a day low of 96.65 and a total volume of 1,085,692.
COV Recent Posts: http://investorshangout.com/Covidien-Plc-COV-50596/
COV Covidien Plc. Recent Headline News
Tracking John Paulson's Paulson & Company Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 12:49AM CST
RKT: 55.82 (-0.08), KOG: 10.14 (+0.38), MEAS: 86.00 (+0.01), HHC: 147.81 (+1.89), AET: 86.01 (+0.46), DLPH: 71.03 (-0.07), DLTR: 65.83 (+3.20), AEM: 26.80 (+0.75), AUXL: 33.15 (+0.12), DG: 66.96 (+0.86), ABBV: 65.40 (-0.10), DXM: 8.28 (+0.02), MNK: 86.72 (+0.74), ATHL: 58.40 (unch), NCQ: 0.70 (+0.01), COV: 97.46 (-0.04), AU: 9.50 (+0.16), MYL: 55.29 (-0.39), IAG: 2.23 (+0.02), FDO: 78.40 (-0.05), MGM: 22.24 (+0.05), GNW: 9.22 (+0.09), HIG: 40.82 (+0.02), NG: 2.89 (+0.09), EQIX: 221.42 (-4.26), HSH: 62.96 (unch), OAS: 26.63 (+0.78), PETM: 78.04 (-0.15), ACT: 259.80 (-6.24), MDT: 71.73 (-0.03), BPOP: 31.83 (-0.17), ENZY: 8.35 (-0.05), FCX: 28.41 (+0.33), GFI: 4.22 (+0.13), CZR: 15.10 (+0.73), CVC: 18.85 (-0.08), CIE: 10.82 (+0.69), CACQ: 10.41 (+0.22), AGN: 210.11 (-2.48), ECA: 18.08 (+0.28), FCH: 10.25 (+0.19), R: 90.81 (+0.26), DTV: 87.08 (-0.14), KMDA: 3.27 (-0.12), ANV: 1.71 (+0.22), MOVE: 20.95 (-0.03), BAC: 16.96 (-0.10), GRFS: 36.63 (+0.25), POST: 35.93 (+0.39), HCA: 67.46 (+0.42), RDN: 16.89 (+0.16), BEE: 12.97 (+0.03), CPWR: 10.27 (+0.11), GLD: 114.52 (+0.84), RLGY: 44.17 (+1.23), MTG: 9.23 (+0.26), HMHC: 19.99 (+0.05), CMCSA: 54.32 (-0.06), CBS: 53.81 (+0.47), BABA: 111.03 (+2.21)
Covidien Achieves CE Mark for the Nellcor(TM) Bedside SpO2 Patient Monitoring System, PM100N
Business Wire - Wed Nov 19, 11:01PM CST
Covidien (NYSE: COV) today announced CE Mark approval for its Nellcor(TM) Bedside SpO2 Patient Monitoring System, PM100N. The system currently is available in the European Economic Area (EEA), Australia and New Zealand. The Nellcor(TM) Bedside SpO2 Patient Monitoring System is the only commercially available bedside pulse oximetry (SpO2) monitor featuring home care and sleep study modes that complies with standards for medical electrical equipment used in the home health care environment.
COV: 97.46 (-0.04)
Mallinckrodt Earnings Beat But No New Guidance
at Investor's Business Daily - Wed Nov 19, 10:42AM CST
Specialty drugmaker Mallinckrodt beat analysts' expectations handily in its fiscal Q4 report, but it didn't provide hoped-for guidance in the wake of an FDA decision that hits one of its best-selling drugs. Mallinckrodt (MNK) stock was down 4% in...
MNK: 86.72 (+0.74), JNJ: 108.11 (-0.65), ACT: 259.80 (-6.24), COV: 97.46 (-0.04)
Uptrend Call Working As Covidien Stock Rises 36.0% (COV)
Comtex SmarTrend(R) - Wed Nov 19, 9:45AM CST
SmarTrend identified an Uptrend for Covidien (NYSE:COV) on May 12th, 2014 at $72.16. In approximately 6 months, Covidien has returned 35.96% as of today's recent price of $98.11.
COV: 97.46 (-0.04)
Stock Market News for November 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 9:10AM CST
Rally in healthcare stocks and easing global growth worries boosted benchmarks to finish in the green on Tuesday
URBN: 31.51 (+1.98), AGN: 210.11 (-2.48), HD: 97.72 (+1.02), ACT: 259.80 (-6.24), GILD: 101.39 (-0.95), PFE: 30.45 (+0.01), COV: 97.46 (-0.04), ALXN: 191.68 (-0.28)
Announcement under Irish Takeover Rules Relevant Securities in Issue - November 19, 2014
Business Wire - Wed Nov 19, 8:41AM CST
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the "Company"
confirms that, as of the close of business on November 18, 2014, the Company's issued share capital, excluding treasury shares, consisted of 452,731,347 ordinary shares, par value US$0.20 per share (the "Ordinary Shares" . The International Securities Identification Number (ISIN) of the Ordinary Shares is IE00B68SQD29.
COV: 97.46 (-0.04)
Medtronic digesting purchases
at Investor's Business Daily - Tue Nov 18, 5:43PM CST
The medical device giant delivered a solid fiscal Q2 report as EPS rose 5% to 96 cents, in line with estimates, on a 4% hike in revenue to $3.67 bil, also meeting estimates. Medtronic (MDT), which is digesting several small acquisitions, said it's...
MDT: 71.73 (-0.03), COV: 97.46 (-0.04)
SmarTrend Watching for Potential Pullback in Shares of Covidien After 3.68% Gain
Comtex SmarTrend(R) - Tue Nov 18, 3:53PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $94.66 to a high of $98.32. Yesterday, the shares gained 3.7%, which took the trading range above the 3-day high of $94.90 on volume of 4.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
COV: 97.46 (-0.04)
Look for Shares of Covidien to Potentially Pullback after Yesterday's 3.68% Rise
Comtex SmarTrend(R) - Tue Nov 18, 3:53PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $94.66 to a high of $98.32. Yesterday, the shares gained 3.7%, which took the trading range above the 3-day high of $94.90 on volume of 4.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
COV: 97.46 (-0.04)
Medtronic (MDT) Posts In Line Earnings, Revenues Beat in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 11:21AM CST
Medtronic Inc.'s (MDT) second-quarter fiscal 2015 adjusted earnings per share (EPS) came in at 96 cents.
BSX: 12.88 (-0.21), MDT: 71.73 (-0.03), ABAX: 52.65 (-1.42), COV: 97.46 (-0.04)
See Why Medtronic Stock Is Surging Today
Sure Dividend - at Seeking Alpha - Tue Nov 18, 10:15AM CST
MDT: 71.73 (-0.03), COV: 97.46 (-0.04)
Medtronic Earnings In Line; Sales Guidance Up
at Investor's Business Daily - Tue Nov 18, 9:55AM CST
Medical-device giant Medtronic (MDT) early Tuesday delivered a solid quarter and modestly bullish revenue guidance as it digests several small acquisitions and prepares for a huge one. Medtronic was up 3.5% in early trading in the stock market today,...
MDT: 71.73 (-0.03), COV: 97.46 (-0.04), STJ: 64.08 (+0.11)
InsiderInsights.com Daily Round Up 11/17/14: SFM, INTX, GNRC, GSAT
InsiderInsights - at Seeking Alpha - Tue Nov 18, 5:55AM CST
HCOM: 25.98 (-0.10), IPHI: 14.75 (+0.31), JBHT: 80.95 (+0.83), COV: 97.46 (-0.04), OPHT: 40.48 (+0.38), COP: 72.95 (+0.82), SFM: 31.52 (+0.09), GOOG: 534.80 (-2.19), GSAT: 2.60 (-0.07), STAY: 18.47 (-0.17), ZOES: 34.19 (+1.05), INTX: 3.77 (+0.04), GNRC: 43.51 (+0.02), HZNP: 12.21 (-0.41), TRUE: 18.06 (+0.48)
Covidien's Test Data Positive for VenaSeal Closure System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:10PM CST
Covidien plc (COV) recently announced six-month results from the VeClose pivotal study, which was carried out to evaluate the safety and efficiency of the VenaSeal closure system, a treatment option for chronic venous disorders.
JNJ: 108.11 (-0.65), BDX: 130.16 (+0.05), BCR: 166.79 (+0.12), COV: 97.46 (-0.04)
Medtronic and Covidien Shareholder Meetings Scheduled for January 6, 2015
Thomson Reuters ONE - Mon Nov 17, 11:30AM CST
MDT: 71.73 (-0.03), COV: 97.46 (-0.04)
Six Month Results of VeClose Study Demonstrate Safety, Effectiveness of the VenaSeal(TM) Closure System
Business Wire - Thu Nov 13, 5:00PM CST
Covidien plc (NYSE:COV) today announced the six-month results of the VeClose pivotal study, which demonstrated the safety and effectiveness of the VenaSeal(TM) closure system* in patients with chronic venous insufficiency (CVI) having symptomatic reflux in the great saphenous vein. The results were presented at American College of Phlebology Annual Congress (ACP 2014) in Phoenix, Ariz.
COV: 97.46 (-0.04)
Form 8.1 - Covidien
Business Wire - Thu Nov 13, 10:17AM CST
Covidien plc:
COV: 97.46 (-0.04)
Insider Trading Alert - CTSH, PSEC And COV Traded By Insiders
at The Street - Thu Nov 13, 9:15AM CST
Stocks with insider trader activity include CTSH, PSEC and COV
COV: 97.46 (-0.04), CTSH: 51.76 (-0.67), PSEC: 9.67 (+0.02)
Covidien Shares Up 28.9% Since SmarTrend's Buy Recommendation (COV)
Comtex SmarTrend(R) - Wed Nov 12, 9:16AM CST
SmarTrend identified an Uptrend for Covidien (NYSE:COV) on May 12th, 2014 at $72.16. In approximately 6 months, Covidien has returned 28.91% as of today's recent price of $93.02.
COV: 97.46 (-0.04)
COV Recent Posts: http://investorshangout.com/Covidien-Plc-COV-50596/
COV Covidien Plc. Recent Headline News
Tracking John Paulson's Paulson & Company Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 12:49AM CST
RKT: 55.82 (-0.08), KOG: 10.14 (+0.38), MEAS: 86.00 (+0.01), HHC: 147.81 (+1.89), AET: 86.01 (+0.46), DLPH: 71.03 (-0.07), DLTR: 65.83 (+3.20), AEM: 26.80 (+0.75), AUXL: 33.15 (+0.12), DG: 66.96 (+0.86), ABBV: 65.40 (-0.10), DXM: 8.28 (+0.02), MNK: 86.72 (+0.74), ATHL: 58.40 (unch), NCQ: 0.70 (+0.01), COV: 97.46 (-0.04), AU: 9.50 (+0.16), MYL: 55.29 (-0.39), IAG: 2.23 (+0.02), FDO: 78.40 (-0.05), MGM: 22.24 (+0.05), GNW: 9.22 (+0.09), HIG: 40.82 (+0.02), NG: 2.89 (+0.09), EQIX: 221.42 (-4.26), HSH: 62.96 (unch), OAS: 26.63 (+0.78), PETM: 78.04 (-0.15), ACT: 259.80 (-6.24), MDT: 71.73 (-0.03), BPOP: 31.83 (-0.17), ENZY: 8.35 (-0.05), FCX: 28.41 (+0.33), GFI: 4.22 (+0.13), CZR: 15.10 (+0.73), CVC: 18.85 (-0.08), CIE: 10.82 (+0.69), CACQ: 10.41 (+0.22), AGN: 210.11 (-2.48), ECA: 18.08 (+0.28), FCH: 10.25 (+0.19), R: 90.81 (+0.26), DTV: 87.08 (-0.14), KMDA: 3.27 (-0.12), ANV: 1.71 (+0.22), MOVE: 20.95 (-0.03), BAC: 16.96 (-0.10), GRFS: 36.63 (+0.25), POST: 35.93 (+0.39), HCA: 67.46 (+0.42), RDN: 16.89 (+0.16), BEE: 12.97 (+0.03), CPWR: 10.27 (+0.11), GLD: 114.52 (+0.84), RLGY: 44.17 (+1.23), MTG: 9.23 (+0.26), HMHC: 19.99 (+0.05), CMCSA: 54.32 (-0.06), CBS: 53.81 (+0.47), BABA: 111.03 (+2.21)
Covidien Achieves CE Mark for the Nellcor(TM) Bedside SpO2 Patient Monitoring System, PM100N
Business Wire - Wed Nov 19, 11:01PM CST
Covidien (NYSE: COV) today announced CE Mark approval for its Nellcor(TM) Bedside SpO2 Patient Monitoring System, PM100N. The system currently is available in the European Economic Area (EEA), Australia and New Zealand. The Nellcor(TM) Bedside SpO2 Patient Monitoring System is the only commercially available bedside pulse oximetry (SpO2) monitor featuring home care and sleep study modes that complies with standards for medical electrical equipment used in the home health care environment.
COV: 97.46 (-0.04)
Mallinckrodt Earnings Beat But No New Guidance
at Investor's Business Daily - Wed Nov 19, 10:42AM CST
Specialty drugmaker Mallinckrodt beat analysts' expectations handily in its fiscal Q4 report, but it didn't provide hoped-for guidance in the wake of an FDA decision that hits one of its best-selling drugs. Mallinckrodt (MNK) stock was down 4% in...
MNK: 86.72 (+0.74), JNJ: 108.11 (-0.65), ACT: 259.80 (-6.24), COV: 97.46 (-0.04)
Uptrend Call Working As Covidien Stock Rises 36.0% (COV)
Comtex SmarTrend(R) - Wed Nov 19, 9:45AM CST
SmarTrend identified an Uptrend for Covidien (NYSE:COV) on May 12th, 2014 at $72.16. In approximately 6 months, Covidien has returned 35.96% as of today's recent price of $98.11.
COV: 97.46 (-0.04)
Stock Market News for November 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 9:10AM CST
Rally in healthcare stocks and easing global growth worries boosted benchmarks to finish in the green on Tuesday
URBN: 31.51 (+1.98), AGN: 210.11 (-2.48), HD: 97.72 (+1.02), ACT: 259.80 (-6.24), GILD: 101.39 (-0.95), PFE: 30.45 (+0.01), COV: 97.46 (-0.04), ALXN: 191.68 (-0.28)
Announcement under Irish Takeover Rules Relevant Securities in Issue - November 19, 2014
Business Wire - Wed Nov 19, 8:41AM CST
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the "Company"
confirms that, as of the close of business on November 18, 2014, the Company's issued share capital, excluding treasury shares, consisted of 452,731,347 ordinary shares, par value US$0.20 per share (the "Ordinary Shares" . The International Securities Identification Number (ISIN) of the Ordinary Shares is IE00B68SQD29. COV: 97.46 (-0.04)
Medtronic digesting purchases
at Investor's Business Daily - Tue Nov 18, 5:43PM CST
The medical device giant delivered a solid fiscal Q2 report as EPS rose 5% to 96 cents, in line with estimates, on a 4% hike in revenue to $3.67 bil, also meeting estimates. Medtronic (MDT), which is digesting several small acquisitions, said it's...
MDT: 71.73 (-0.03), COV: 97.46 (-0.04)
SmarTrend Watching for Potential Pullback in Shares of Covidien After 3.68% Gain
Comtex SmarTrend(R) - Tue Nov 18, 3:53PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $94.66 to a high of $98.32. Yesterday, the shares gained 3.7%, which took the trading range above the 3-day high of $94.90 on volume of 4.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
COV: 97.46 (-0.04)
Look for Shares of Covidien to Potentially Pullback after Yesterday's 3.68% Rise
Comtex SmarTrend(R) - Tue Nov 18, 3:53PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $94.66 to a high of $98.32. Yesterday, the shares gained 3.7%, which took the trading range above the 3-day high of $94.90 on volume of 4.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
COV: 97.46 (-0.04)
Medtronic (MDT) Posts In Line Earnings, Revenues Beat in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 11:21AM CST
Medtronic Inc.'s (MDT) second-quarter fiscal 2015 adjusted earnings per share (EPS) came in at 96 cents.
BSX: 12.88 (-0.21), MDT: 71.73 (-0.03), ABAX: 52.65 (-1.42), COV: 97.46 (-0.04)
See Why Medtronic Stock Is Surging Today
Sure Dividend - at Seeking Alpha - Tue Nov 18, 10:15AM CST
MDT: 71.73 (-0.03), COV: 97.46 (-0.04)
Medtronic Earnings In Line; Sales Guidance Up
at Investor's Business Daily - Tue Nov 18, 9:55AM CST
Medical-device giant Medtronic (MDT) early Tuesday delivered a solid quarter and modestly bullish revenue guidance as it digests several small acquisitions and prepares for a huge one. Medtronic was up 3.5% in early trading in the stock market today,...
MDT: 71.73 (-0.03), COV: 97.46 (-0.04), STJ: 64.08 (+0.11)
InsiderInsights.com Daily Round Up 11/17/14: SFM, INTX, GNRC, GSAT
InsiderInsights - at Seeking Alpha - Tue Nov 18, 5:55AM CST
HCOM: 25.98 (-0.10), IPHI: 14.75 (+0.31), JBHT: 80.95 (+0.83), COV: 97.46 (-0.04), OPHT: 40.48 (+0.38), COP: 72.95 (+0.82), SFM: 31.52 (+0.09), GOOG: 534.80 (-2.19), GSAT: 2.60 (-0.07), STAY: 18.47 (-0.17), ZOES: 34.19 (+1.05), INTX: 3.77 (+0.04), GNRC: 43.51 (+0.02), HZNP: 12.21 (-0.41), TRUE: 18.06 (+0.48)
Covidien's Test Data Positive for VenaSeal Closure System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:10PM CST
Covidien plc (COV) recently announced six-month results from the VeClose pivotal study, which was carried out to evaluate the safety and efficiency of the VenaSeal closure system, a treatment option for chronic venous disorders.
JNJ: 108.11 (-0.65), BDX: 130.16 (+0.05), BCR: 166.79 (+0.12), COV: 97.46 (-0.04)
Medtronic and Covidien Shareholder Meetings Scheduled for January 6, 2015
Thomson Reuters ONE - Mon Nov 17, 11:30AM CST
MDT: 71.73 (-0.03), COV: 97.46 (-0.04)
Six Month Results of VeClose Study Demonstrate Safety, Effectiveness of the VenaSeal(TM) Closure System
Business Wire - Thu Nov 13, 5:00PM CST
Covidien plc (NYSE:COV) today announced the six-month results of the VeClose pivotal study, which demonstrated the safety and effectiveness of the VenaSeal(TM) closure system* in patients with chronic venous insufficiency (CVI) having symptomatic reflux in the great saphenous vein. The results were presented at American College of Phlebology Annual Congress (ACP 2014) in Phoenix, Ariz.
COV: 97.46 (-0.04)
Form 8.1 - Covidien
Business Wire - Thu Nov 13, 10:17AM CST
Covidien plc:
COV: 97.46 (-0.04)
Insider Trading Alert - CTSH, PSEC And COV Traded By Insiders
at The Street - Thu Nov 13, 9:15AM CST
Stocks with insider trader activity include CTSH, PSEC and COV
COV: 97.46 (-0.04), CTSH: 51.76 (-0.67), PSEC: 9.67 (+0.02)
Covidien Shares Up 28.9% Since SmarTrend's Buy Recommendation (COV)
Comtex SmarTrend(R) - Wed Nov 12, 9:16AM CST
SmarTrend identified an Uptrend for Covidien (NYSE:COV) on May 12th, 2014 at $72.16. In approximately 6 months, Covidien has returned 28.91% as of today's recent price of $93.02.
COV: 97.46 (-0.04)
